Angiotech: Specialty Pharma in the Device World
Executive Summary
Angiotech positions itself as the first specialty pharmaceutical company dedicated to the drug/device interface. Best known as Boston-Scientific's pharmaceutical partner on the Taxus drug-eluting stent, Angiotech has created a large body of intellectual property around drug-device combinations. Focusing on the essential biological mechanisms involved in device failures, the company develops existing drugs for new applications in combination products for surgical markets, and it also owns a broad-based portfolio of drug eluting biomaterials. Now, as it looks to life after drug-eluting stents, Angiotech has plans to offer drug plus device combinations in peripheral vascular disease, orthopedics, ob/gyn surgery, and anti-infective coatings. It will thus face the challenge of managing, as a small to mid-sized company, a great variety of projects with limited resources. To lessen reliance on partners, going forward, it aims to capture an increasing proportion of revenues from product sales, taking some products from preclinical stage to market itself. But as a mid-sized company, it might have to choose between sacrificing a percentage of product sales to partners that provide development or distribution expertise that it doesn't have, or narrowly focusing on markets that it can address itself, but limiting its opportunities in a niche specialty.
You may also be interested in...
TYRX: Is This the Model for Drug/Device Convergence?
TYRX has a novel device - an antibiotic-impregnated envelope designed to prevent infections in CRM implants - that could create signifcant opportunities, not just for itself, but also for large CRM companies looking to differentiate their devices in a flat, crowded market. Convergence has fallen on hard times recently, but TYRX hopes to succeed where others have failed by stripping risk out of drug/device convergence.
Angiotech acquires Device Company, Takes Control of its Destiny
Ever since drug-eluting stents became such an overwhelming success, the health care products industry has been trying to wrap its arms around convergence opportunities, in which the combination of drugs and devices is worth more than the sum of the parts and pieces. The ongoing debate has been: which part of combination products is it better to own--the drug or the device? According to one company that would probably define itself as the only "pure play" in convergence, Angiotech Pharmaceuticals Inc., the answer is: both. Angiotech just acquired diversified device manufacturer AMI Holdings.
Gauging the Risks of Financing Convergence Start-Ups
A handful of recent biotech-device company deals have highlighted the potential of drug-device convergence as natural extensions of the ever-popular repurposing and drug delivery models espoused by investors aiming to reduce the risks associated with drug discovery. Venture capitalists are eager to get in on the game, but drug and device hybrid business models are few and far between. True convergence start-ups remain thin on the ground, a fact VCs say reflects the additive nature of drug risk and device risk.